DNAJB2

Across TCGA pan-cancer cohorts, DNAJB2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated DNAJB2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DNAJB2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DNAJB2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where DNAJB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.986	0.887	.007	32	view →
CCRCC	DFS	Tertile	All	1.000	0.459	.007	13	view →
LUAD	DFS	Quartile	All	0.846	0.996	.005	7	view →
LSCC	DFS	Tertile	II,III,IV	0.567	0.884	.035	6	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.477	.018	4	view →
GBM	DFS	Tertile	All	0.895	0.742	.029	3	view →
PDAC	OS	Quartile	II,III,IV	1.000	0.817	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

DNAJB2–HNSC (DFS)

Open the HNSC breakdown →